MEDTRONIC PLC: CITIGROUP LOWERS TARGET PRICE FROM $117 TO $110
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MDT?
Source: moomoo
- Target Price Adjustment: Citigroup Group has reduced the target price for Medtronic PLC from $117 to $110.
- Market Impact: This adjustment reflects changes in market conditions and expectations for Medtronic's performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 88.650
Low
102.00
Averages
111.76
High
120.00
Current: 88.650
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
- Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
- Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
Analysis of High-Yield Stock Investment Opportunities
- Stability of Enterprise Products: Enterprise Products Partners showcases a robust 5.7% dividend yield and a 27-year history of increasing dividends, reflecting its cash flow stability throughout energy cycles; despite market volatility, its fee-based revenue model ensures reliable income.
- Resilience of Realty Income: Realty Income boasts a 5.2% dividend yield and an impressive 31-year dividend growth record, demonstrating its investment strength in the retail sector, maintaining a reasonable 75% FFO payout ratio even through multiple economic downturns, highlighting its strong access to capital markets.
- Growth Potential of Medtronic: While Medtronic's 3.2% dividend yield is lower, its 48-year dividend growth streak and the upcoming spin-off of its diabetes business could enhance profitability; coupled with new product launches, this is expected to drive stock price appreciation.
- Investment Timing in the Market: In the current uncertain market environment, investing in reliable high-yield stocks like Enterprise, Realty Income, and Medtronic could be a strategic move for long-term wealth growth, especially for existing shareholders considering increasing their positions.
See More
MEDTRONIC PLC: CITIGROUP LOWERS TARGET PRICE FROM $117 TO $110
- Target Price Adjustment: Citigroup Group has reduced the target price for Medtronic PLC from $117 to $110.
- Market Impact: This adjustment reflects changes in market conditions and expectations for Medtronic's performance.
See More
Intuitive Surgical: Advantages of a Market Leader
- Market Share Advantage: Intuitive Surgical holds an impressive 86% share of the U.S. robotic surgical systems market, and despite facing competition, its dominance in soft tissue procedures continues to yield excellent financial results, making it attractive for long-term investors.
- Financial Flexibility: As of 2025, Intuitive Surgical reported total assets of $20.5 billion against total liabilities of $2.5 billion, with a minimal percentage of long-term debt, providing the company with significant financial stability and flexibility during economic fluctuations.
- Increased Competitive Pressure: With Medtronic's Hugo system and Johnson & Johnson's Ottava system nearing approval, Intuitive Surgical will encounter heightened market competition; however, its high switching costs and proven success over two decades will help maintain its market leadership.
- Sustained Growth Potential: Despite intensifying industry competition, Intuitive Surgical's market remains underpenetrated, and with its leading market share and high customer loyalty, the company is well-positioned for continued stable financial growth in the future.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
- Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
- Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
Analysis of High-Yield Stock Investment Opportunities
- Stability of Enterprise Products: Enterprise Products Partners showcases a robust 5.7% dividend yield and a 27-year history of increasing dividends, reflecting its cash flow stability throughout energy cycles; despite market volatility, its fee-based revenue model ensures reliable income.
- Resilience of Realty Income: Realty Income boasts a 5.2% dividend yield and an impressive 31-year dividend growth record, demonstrating its investment strength in the retail sector, maintaining a reasonable 75% FFO payout ratio even through multiple economic downturns, highlighting its strong access to capital markets.
- Growth Potential of Medtronic: While Medtronic's 3.2% dividend yield is lower, its 48-year dividend growth streak and the upcoming spin-off of its diabetes business could enhance profitability; coupled with new product launches, this is expected to drive stock price appreciation.
- Investment Timing in the Market: In the current uncertain market environment, investing in reliable high-yield stocks like Enterprise, Realty Income, and Medtronic could be a strategic move for long-term wealth growth, especially for existing shareholders considering increasing their positions.
See More
MEDTRONIC PLC: CITIGROUP LOWERS TARGET PRICE FROM $117 TO $110
- Target Price Adjustment: Citigroup Group has reduced the target price for Medtronic PLC from $117 to $110.
- Market Impact: This adjustment reflects changes in market conditions and expectations for Medtronic's performance.
See More
Intuitive Surgical: Advantages of a Market Leader
- Market Share Advantage: Intuitive Surgical holds an impressive 86% share of the U.S. robotic surgical systems market, and despite facing competition, its dominance in soft tissue procedures continues to yield excellent financial results, making it attractive for long-term investors.
- Financial Flexibility: As of 2025, Intuitive Surgical reported total assets of $20.5 billion against total liabilities of $2.5 billion, with a minimal percentage of long-term debt, providing the company with significant financial stability and flexibility during economic fluctuations.
- Increased Competitive Pressure: With Medtronic's Hugo system and Johnson & Johnson's Ottava system nearing approval, Intuitive Surgical will encounter heightened market competition; however, its high switching costs and proven success over two decades will help maintain its market leadership.
- Sustained Growth Potential: Despite intensifying industry competition, Intuitive Surgical's market remains underpenetrated, and with its leading market share and high customer loyalty, the company is well-positioned for continued stable financial growth in the future.
See More
